Nicotinic acid mononucleotide
Based on 1 publication(s) in Google Scholar
Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD+ biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD+ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD+ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.08%
- CAS 番号: 321-02-8
- 分子式: C11H14NO9P
- 分子量:335.20
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-123033A
Nicotinamide riboside chlorideEndogenous Metabolite -
HY-B0445
NAD+Endogenous Metabolite -
HY-W104368
Nicotinic acid ribosideNAD+ Precursor -
HY-B2156
Menaquinone-4Endogenous Metabolite -
HY-10071
Y-27632ROCK Inhibitor -
HY-F0004
FosribnicotinamideNAD+ Intermediate -
HY-N6821
2-O-α-D-Glucopyranosyl-L-ascorbic AcidGlucoside Derivative -
HY-B2156R
Menaquinone-4 (Standard)Endogenous Metabolite -
HY-B1278
D-α-Tocopherol acetateEndogenous Metabolite -
HY-113472
N-Methyl-4-pyridone-3-carboxamideNAD Metabolite -
HY-B2223
Thiamine nitrateVitamin B1 Supplement -
HY-119937
ROCK inhibitor-2ROCK Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Nicotinic acid mononucleotide
MoreEndogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
Nicotinic acid mononucleotide (0-250 μM; assay duration) inhibits the NAD+ hydrolase activity of full-length human SARM1 by binding to its N-terminal ARM domain; its IC50 is 93.3 μM in the absence of NMN, while this inhibitory effect is attenuated in the presence of 5 μM NMN (IC50 = 147.2 μM)[1].
Nicotinic acid mononucleotide delays axonal degeneration of mammalian axons by restoring reduced intracellular NAD+ levels[3].
Nicotinic acid mononucleotide (NAM) increases the expression of Sirt1 and the phosphorylation level of eNOS in human umbilical vein endothelial cells (HUVECs) treated with high glucose[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (8-week-old male; streptozotocin-induced diabetic)[4]
-
Dosage:400 mg/kg/day
-
Administration:i.p.; daily; 8 weeks
-
Result:Partially increased myocardial NAD+ levels in diabetic mice.
Partially reversed impaired left ventricular ejection fraction (LVEF) and fractional shortening (FS) relative to untreated diabetic mice.
Improved myocardial ultrastructural abnormalities (reduced Z-line misalignment, mitochondrial swelling, and myofibril disorganization).
Increased myocardial capillary density relative to untreated diabetic mice.
Reduced myocardial expression of fibrosis markers TGF-β1 and collagen I relative to untreated diabetic mice.
Restored myocardial Sirt1 mRNA and protein expression relative to untreated diabetic mice.
Had no effect on blood glucose or body weight in diabetic mice, and no significant effect on interventricular septal thickness (IVSD) or left ventricular posterior wall thickness (LVPWD).
化学情報
-
CAS 番号 321-02-8
-
性状 Solid
-
分子量 335.20
-
分子式 C11H14NO9P
-
Color White to off-white
-
SMILES
O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1[N+]2=CC=CC(C([O-])=O)=C2
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Diabetes Res Clin Pract
ACMSD mediated de novo NAD+ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy. [Abstract]2023 Dec:206:111014. PMID: 37977551
溶剤 & 溶解度
体外:
H2O : 10 mg/mL (29.83 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Sasaki Y, et al. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp Neurol. 2021;345:113842. [Content Brief]
[2]. O'Hara JK, et al. Targeting NAD+ metabolism in the human malaria parasite Plasmodium falciparum. PLoS One. 2014;9(4):e94061. Published 2014 Apr 18. [Content Brief]
[3]. Khan JA, et al. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007;11(5):695-705. [Content Brief]
[4]. Zeng F, et al. ACMSD mediated de novo NAD+ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy. Diabetes Res Clin Pract. 2023;206:111014. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.9833 mL | 14.9165 mL | 29.8329 mL | 74.5823 mL |
| 5 mM | 0.5967 mL | 2.9833 mL | 5.9666 mL | 14.9165 mL | |
| 10 mM | 0.2983 mL | 1.4916 mL | 2.9833 mL | 7.4582 mL | |
| 15 mM | 0.1989 mL | 0.9944 mL | 1.9889 mL | 4.9722 mL | |
| 20 mM | 0.1492 mL | 0.7458 mL | 1.4916 mL | 3.7291 mL | |
| 25 mM | 0.1193 mL | 0.5967 mL | 1.1933 mL | 2.9833 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Nicotinic acid mononucleotide 関連分類
HY-128700 関連分類
Powered by Bioz